Market research
OCX OncoCyte Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 5.4167
- Dividend yield
- Not available
- Beta
- 0.99
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US68235C1071
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 5.4167
- Dividend yield
- Not available
- Beta
- 0.99
About
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OCX discussion.
5 years, 4 months ago
OncoCyte Corporation Common Stock is currently in a long term uptrend where the price is trading 43.1% above its 200 day moving average.
From a valuation standpoint, the stock is 77.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 298.9.
OncoCyte Corporation Common Stock's total revenue rose by inf% to $503K since the same quarter in the previous year.
Its net income has increased by 20.7% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.8% to $-6M since the same quarter in the previous year.
Based on the above factors, OncoCyte Corporation Common Stock gets an overall score of 4/5.